Cardiol Therapeutics to Present at TD Cowen Health Care Conference

Cardiol Therapeutics ( (TSE:CRDL) ) has provided an update.

Cardiol Therapeutics announced its participation in the TD Cowen 45th Annual Health Care Conference, highlighting its ongoing clinical trials and FDA-approved studies for its lead drug candidate, CardiolRx™, aimed at treating heart diseases like recurrent pericarditis and acute myocarditis. The company’s strategic focus on innovative therapies positions it as a significant player in the healthcare sector, potentially impacting stakeholders through advancements in heart disease treatment.

More about Cardiol Therapeutics

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease treatment. Its lead product, CardiolRx™, is a cannabidiol oral solution in clinical development for heart disease, with FDA authorization for studies on recurrent pericarditis and acute myocarditis. Cardiol is also developing CRD-38, a novel drug formulation for heart failure.

YTD Price Performance: -16.06%

Average Trading Volume: 311,552

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $93.85M

For detailed information about CRDL stock, go to TipRanks’ Stock Analysis page.